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Institute, Concord, MA, USA, 3Novartis Pharma AG, Basel,
Switzerland, 4Novartis Pharmaceuticals Corporation, Florham Park, NJ,
USA, 5Duke University Medical Center, Durham, NC, USA
OBJECTIVES: The reporting of blood pressure (BP) is known to
be affected by errors due to digit preferences or rounding to the
closest multiple of ten. If this occurs completely randomly, esti-
mates of effect will be attenuated and the power of statistical
tests reduced. Systematic bias can also occur if, for instance,
physicians round measurements differentially for high or low
risk patients. We examined this with data taken from an ongoing
naturalistic study of the impact of a hypertension control edu-
cation program. METHODS: Systolic and diastolic blood pres-
sure measurements were reported by physicians at the time of
enrolling hypertensive patients. We derived the distribution of
the terminal digit of the measurements and compared the prob-
ability of reporting a terminal zero when the measurement was
above or below the threshold of BP control (140/90 mm Hg) and
by patients’ baseline characteristics. RESULTS: Analyses were
based on an interim cut of data on 4594 patients, of which
47.5% were male with mean age 56 years (SD = 13.5). There
was clear evidence of digit preference by physicians: e.g., 46.3%
of systolic BP measurements ended with 0, and 43.3% were even
numbers. The probability of a terminal zero was slightly higher
above the systolic BP control threshold: 47.1% above vs. 44.4%
below (p-value = 0.09). Rounded values were also more likely
for females (47.9 vs. 44.6%, p-value = 0.02) and patients 65
years or older (49.7 vs. 45.2%, p = 0.01), but did not differ by
levels of other cardiovascular risk factors. Measurements of dias-
tolic BP were also rounded very frequently (44.6%), but dif-
ferences by patient characteristics were not signiﬁcant.
CONCLUSION: Physicians frequently round to the closest mul-
tiple of ten when reporting BP measurements, and do so slightly
more frequently for female and older patients, and those further
from the threshold deﬁning BP control.
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DYNAMIC OPTIMIZATION IN THE TREATMENT OF
HYPERLIPIDEMIA
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OBJECTIVES: The ﬁeld of pharmacoeconomics has evolved
rapidly over the past two decades and the methodological rigor
and sophistication found in contemporary pharmacoeconomic
analyses are remarkable. However, many useful analytic methods
have yet to be adopted or fully considered, techniques that may
be particularly well suited for our ﬁeld. One promising method,
long used in economics and physics, is dynamic optimization,
which can identify optimal treatment pathways for patients suf-
fering from diseases with progressive treatment options, both
types and doses, where the value of aggressive treatment is of
interest. Using hyperlipidemia as a case study, we propose mul-
tiple mathematical and statistical methods to identify the optimal
(both cost-minimizing and net beneﬁt-maximizing) hyperlipi-
demia treatment trajectories that consider the options of diet and
exercise and multiple-dose statin therapy to bring a patient, or
population of patients, to a pre-determined cholesterol goal (e.g.
their NCEP goal). METHODS: Discrete-time mathematical pro-
gramming models, both deterministic and stochastic, are devel-
oped to optimize over the combinatorial set of clinically feasible
hyperlipidemia treatment strategies. Contemporary cardiovascu-
lar risk equations, costs, and side effect risk data are used to pop-
ulate the models and programs. RESULTS: Initial results suggest
that optimal (economic) hyperlipidemia treatment strategy varies
based upon patient proﬁle and risk for CVD, but in the major-
ity of cases more aggressive statin therapy results in higher
expected net beneﬁts and lower expected costs than current treat-
ment approaches; speciﬁcally, gradual titration regimens. Analy-
ses considering longer term horizons (e.g., >1 year) tend to
increases net beneﬁt differences more than cost differences.
CONCLUSION: The preliminary evidence in our research sug-
gests that considerable cost savings (and net beneﬁts gains) are
possible if hyperlipidemia patients are treated aggressively to
reduce their cardiovascular risk as quickly as possible. These
methods are generalizable to other disease areas and are useful
in economic evaluation of treatment patterns.
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FACTOR SCREENING FOR PARSIMONY OF VARIABLES IN
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OBJECTIVES: This research applies factor screening techniques
to a decision tree model of the ﬁrst 30 days following an acute
coronary event. The objective is to determine which input vari-
ables most affect the total cost and to evaluate how well a meta-
model composed of fewer variables can replace the decision tree
model. METHODS: Factor screening techniques are often used
in defense simulations to examine simultaneously many input
variables to identify those with a signiﬁcant effect on a selected
response (output). The original model was built using TreeAge
Pro Health care and parameterized to replicate 30-day results
from the Clopidogrel in Unstable angina to prevent Recurrent
ischemic Events (CURE) trial. The model had 44 input variables
(28 relatively independent factors) comparing 30-day results for
clopidogrel plus aspirin to a hypothetical alternative. Ranges of
uncertainty were assigned to the input variables. A 2 k Fractional
Factorial of Resolution IV (FF) and a Folded-over Sequential
Bifurcation (SB-X) method were used to identify important
factors. A metamodel was generated using a Central Composite
Design and dropping the effects with F-ratio less than 2.0.
RESULTS: Both the FF and SB-X methods identiﬁed the same
seven factors (ﬁve costs and two probabilities). In addition to the
main effects, the metamodel had only two second-order terms,
and no quadratic effects. When a Nearly Orthogonal Latin
Hypercube Design with 256 observations was used to sample the
entire experimental region (including all 28 factors), the reduced
metamodel could account for more than 99% of the variation
observed over the entire experimental region. (Error: 0.702%)
CONCLUSION: Results from the 44-variable decision-tree
model were matched by a nine-term metamodel. When factor
screening can reduce the number inputs that must be speciﬁed,
the data needed to predict responses can be greatly reduced.
Further work investigates factor screening and developing cor-
responding metamodels for stochastic models.
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OBJECTIVES: The study objective was to examine the preva-
lence and factors associated with potential drug-drug interac-
tions on ACE Inhibitors prescription in the U.S. from
2001–2004. METHODS: This project proposed a secondary
data analysis using the U.S. National Ambulatory Medical Care
Survey (NAMCS) conducted by the National Center for Health
Statistics. A series of population weighted descriptive analyses
were performed to evaluate the prevalence of potential drug
interactions. Eisenberg’s sociologic theory was adopted to iden-
tify the potential patient and physician’s characteristics asso-
ciated with the presence of drug interactions. A weighted
multivariate logistic regression model was used to examine the
signiﬁcance of these predictor variables with 0.05 alpha level.
RESULTS: From 2001 to 2004, there were 125.6 million visits
where ACE inhibitors were prescribed for the treatment of
hypertension in the U.S., 48.1 million (38.3%) of these visits
encountered potential drug interactions. Signiﬁcant patient char-
acteristic included sex (OR = 1.57), pay type (OR =< 0.001),
region (OR = 2.41), age (P < 0.001), and number of medications
taken (P < 0.001). Signiﬁcant physician characteristics included
metropolitan region (OR = 0.22), ofﬁce setting (OR =< 0.001),
physician employment (OR =< 0.001), practice ownership (OR
=< 0.001), e-mail consultation (OR = 5.79), payment sources
(OR =< 0.001), and specialty; pediatrics (OR = 139.61), cardi-
ology (OR = 61.30), dermatology (OR =< 0.001), urology
(<0.001), and otolaryngology (OR =< 0.001). CONCLUSION:
The study reveals a very high prevalence rate (38.3%) and rec-
ognizes various patient and physician’s characteristics associated
with potential drug interactions with ACE Inhibitors. From the
public safety viewpoint, it is imperative for the interdisciplinary
health providers to identify new strategies to avoid drug inter-
actions, particularly for the patients with polypharmacy status.
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MANAGED CARE POPULATION
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs) (LDL-C, HDL-C, and TG) is associated with 
an increased risk of cardiovascular events (CVE). Data compar-
ing combination lipid therapy effects on multiple lipid abnor-
malities and CVE reduction are limited. We modeled CVE risk
reduction with extended release niacin/simvastatin (ERN/S), sim-
vastatin/ezetimibe (S/E), extended release niacin (ERN), simvas-
tation (S), and ezetimibe (E), in a large managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database if they had a lipid panel between January
1, 2000 and December 31, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Cardiovascular risk
and CVEs (determined by ICD-9/CPT codes, prescription
records, and ER visits/hospitalizations) for each patient were
identiﬁed, and OLV achievement was modeled using product
labeling at maximum doses (assuming additive effects for
ERN/S). Population CVE rate during 30 ± 12 months of follow-
up was 15.16% with an odds ratio 0.69 (CI: 0.61 to 0.81).
Achievement (18%) vs non-achievement (82%) of OLVs was uti-
lized to estimate CVE rates associated with modeled OLV
achievement rates. RESULTS: We analyzed 44,351 patients;
50% male, age 65 ± 13 years. Modeled lipid therapy resulted in
combined OLV achievement of: ERN/S 66.2%, S/E 48.4%, ERN
36.4%, S 46.3%, and E 18.4% (x2 p < 0.05 all vs baseline;
ERN/S vs S/E, ERN, and S; S/E vs S and E). Based upon achieve-
ment of OLV, the predicted population CVE rates were reduced
from baseline (15.16%) to: ERN/S 9.4 % (RRR: 38%), S/E
11.5% (RRR: 24%), ERN 13.0% (RRR: 14%), S 11.8% (RRR:
22%), and E 15.1% (RRR: 0.4%)(p < 0.05 for all except E vs
baseline; ERN/S vs S/E, ERN, and S; S/E vs E). CONCLUSION:
In this MCO population, OLVs were more frequently achieved
with ERN/S versus S/E, ERN, and S. Attaining combined OLVs
with combination ERN/S resulted in signiﬁcant reductions in
projected CVE rates.
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USING AN INTERNATIONAL DATABASE OF ACUTE
CORONARY EVENTS TO ASSESS TODAY’S PRACTICE
PATTERNS AND DESCRIBE TREATMENT STRATEGIES IN THE
HOSPITAL SETTING
Nasuti PI, Hamad B,Yeung E
IMS Health, London, UK
OBJECTIVES: To assess the current treatment of Acute Coro-
nary Syndromes in the hospital setting and determine whether
treatment would demonstrate comparable patterns around
Europe. METHODS: The IMS Acute Cardiovascular Analyzer
is an international database designed to track patients present-
ing with an ACS in Germany, France, Italy, Spain and UK.
RESULTS: A total of 8091 ACS cases were enrolled between
November 2005 and November 2006. Data were reported from
around 500 cardiologists. Baseline patient characteristics were:
female 32%, age over 65 years 43%, hypertension 68%, dys-
lipidemia 69%, diabetes 32%, obesity 29%, coronary artery
disease 12%. Most common treatments received in hospital
were: COX inhibitors 95%, Statins 86%, clopidogrel 79%, Beta-
blockers 72% and ACE inhibitors 69%. Thrombolytic agents
were administered to 32% of STEMI patients (68% in UK vs
7% in Germany) and 5% of them also received a primary PCI.
UA/NSTEMI patients had a PCI (50%) and mostly >12 hours
after onset of symptoms (66%). In Germany has the highest
number of PCIs performed within 12 hours after the acute event
(50%). Before hospital admission 25% of STEMI vs 38% of
NSTEMI/UA patients were on statins. Approximately 68% of
STEMI patients were discharged on clopidogrel and 81% on
statins. The in-hospital mortality rates were 8% (STEMI) vs 2%
(UA/NSTEMI). For the majority of the ACS patients (55%) the
length of stay in hospital was 5–10 days. CONCLUSION: These
data can be used to identify key factors determining therapeutic
decision making concerning ACS treatment in Europe.
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IS META-ANALYSIS ALWAYS A GOOD IDEA?
Xenakis JG, Huybrechts KF, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: Is it enough to check for statistical heterogeneity
before plunging into a meta-analysis? For example, there are
many clinical trials of rhythm control drugs for atrial ﬁbrillation
(AF), suggesting a meta-analysis is the way to go. Is it?
METHODS: A MEDLINE search yielded 347 studies, of which
20 met strict inclusion criteria. Only randomized, blinded studies
of adults with ECG-conﬁrmed AF or atrial ﬂutter recurrence
were considered. Studies had to compare antiarrhythmic agents
or antiarrhythmics with placebo. Crossover studies and studies
of AF after cardiac surgery were excluded. RESULTS: After
detailed review, we decided that, in contrast with a published
systematic review, meta-analysis was not appropriate due to
intractable heterogeneity in study designs. Although recurrence
risk differs substantially between chronic and paroxysmal AF,
